PortfoliosLab logoPortfoliosLab logo
GMED vs. EW
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

GMED vs. EW - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Globus Medical, Inc. (GMED) and Edwards Lifesciences Corporation (EW). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, GMED achieves a -8.33% return, which is significantly lower than EW's 1.99% return. Over the past 10 years, GMED has outperformed EW with an annualized return of 12.87%, while EW has yielded a comparatively lower 10.51% annualized return.


GMED

1D
1.07%
1M
-5.62%
YTD
-8.33%
6M
-9.83%
1Y
38.45%
3Y*
11.06%
5Y*
1.52%
10Y*
12.87%

EW

1D
1.25%
1M
1.36%
YTD
1.99%
6M
0.83%
1Y
15.44%
3Y*
-1.27%
5Y*
-3.48%
10Y*
10.51%
*Multi-year figures are annualized to reflect compound growth (CAGR)

GMED vs. EW - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
GMED
Globus Medical, Inc.
-8.33%5.56%55.21%-28.25%2.87%10.70%10.77%36.04%5.30%65.66%
EW
Edwards Lifesciences Corporation
1.99%15.16%-2.91%2.20%-42.41%42.00%17.32%52.31%35.90%20.29%

Correlation

The correlation between GMED and EW is 0.40, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.40

Correlation (3Y)
Calculated over the trailing 3-year period

0.37

Correlation (5Y)
Calculated over the trailing 5-year period

0.46

Correlation (10Y)
Calculated over the trailing 10-year period

0.45

Correlation (All Time)
Calculated using the full available price history since Aug 3, 2012

0.40

Fundamentals

Market Cap

GMED:

$11.06B

EW:

$50.49B

EPS

GMED:

$4.29

EW:

$1.87

PE Ratio

GMED:

18.67

EW:

46.47

PEG Ratio

GMED:

0.20

EW:

1.49

PS Ratio

GMED:

3.53

EW:

8.06

PB Ratio

GMED:

2.34

EW:

4.89

Total Revenue (TTM)

GMED:

$3.10B

EW:

$6.30B

Gross Profit (TTM)

GMED:

$1.58B

EW:

$4.92B

EBITDA (TTM)

GMED:

$803.34M

EW:

$1.44B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

GMED vs. EW — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GMED
GMED Risk / Return Rank: 7272
Overall Rank
GMED Sharpe Ratio Rank: 6868
Sharpe Ratio Rank
GMED Sortino Ratio Rank: 7575
Sortino Ratio Rank
GMED Omega Ratio Rank: 7272
Omega Ratio Rank
GMED Calmar Ratio Rank: 7373
Calmar Ratio Rank
GMED Martin Ratio Rank: 7474
Martin Ratio Rank

EW
EW Risk / Return Rank: 6262
Overall Rank
EW Sharpe Ratio Rank: 6363
Sharpe Ratio Rank
EW Sortino Ratio Rank: 5858
Sortino Ratio Rank
EW Omega Ratio Rank: 5555
Omega Ratio Rank
EW Calmar Ratio Rank: 6666
Calmar Ratio Rank
EW Martin Ratio Rank: 6767
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GMED vs. EW - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Globus Medical, Inc. (GMED) and Edwards Lifesciences Corporation (EW). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


GMEDEWDifference
Sharpe ratioReturn per unit of total volatility

+0.16

Sortino ratioReturn per unit of downside risk

+0.79

Omega ratioGain probability vs. loss probability

1.23

1.13

+0.10

Calmar ratioReturn relative to maximum drawdown

1.75

1.22

+0.53

Martin ratioReturn relative to average drawdown

4.46

3.01

+1.45

GMED vs. EW - Sharpe Ratio Comparison

The current GMED Sharpe Ratio is 0.79, which is comparable to the EW Sharpe Ratio of 0.64. The chart below compares the historical Sharpe Ratios of GMED and EW, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

GMED vs. EW - Drawdown Comparison

The maximum GMED drawdown since its inception was -47.91%, smaller than the maximum EW drawdown of -54.32%. Use the drawdown chart below to compare losses from any high point for GMED and EW.


Loading charts...

Drawdown Indicators


GMEDEWDifference

Max Drawdown

Largest peak-to-trough decline

-47.91%

-54.32%

+6.41%

Max Drawdown (1Y)

Largest decline over 1 year

-22.10%

-12.73%

-9.37%

Max Drawdown (3Y)

Largest decline over 3 years

-44.40%

-37.53%

-6.87%

Max Drawdown (5Y)

Largest decline over 5 years

-47.91%

-54.32%

+6.41%

Max Drawdown (10Y)

Largest decline over 10 years

-47.91%

-54.32%

+6.41%

Current Drawdown

Current decline from peak

-17.33%

-33.46%

+16.13%

Average Drawdown

Average peak-to-trough decline

-15.33%

-14.50%

-0.83%

Ulcer Index

Depth and duration of drawdowns from previous peaks

8.65%

5.15%

+3.50%

Volatility

GMED vs. EW - Volatility Comparison

Globus Medical, Inc. (GMED) has a higher volatility of 10.78% compared to Edwards Lifesciences Corporation (EW) at 7.56%. This indicates that GMED's price experiences larger fluctuations and is considered to be riskier than EW based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


GMEDEWDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.78%

7.56%

+3.22%

Volatility (6M)

Calculated over the trailing 6-month period

23.54%

19.01%

+4.53%

Volatility (1Y)

Calculated over the trailing 1-year period

48.64%

24.36%

+24.28%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

38.04%

32.66%

+5.38%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

35.54%

32.26%

+3.28%

Dividends

GMED vs. EW - Dividend Comparison

Neither GMED nor EW has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

GMED vs. EW - Financials Comparison

This section allows you to compare key financial metrics between Globus Medical, Inc. and Edwards Lifesciences Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


500.00M1.00B1.50B20222023202420252026
759.85M
1.65B
(GMED) Total Revenue
(EW) Total Revenue
Values in USD except per share items

GMED vs. EW - Profitability Comparison

The chart below illustrates the profitability comparison between Globus Medical, Inc. and Edwards Lifesciences Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%202220232024202520260
78.2%
Portfolio components
GMED - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Globus Medical, Inc. reported a gross profit of 0.00 and revenue of 759.85M. Therefore, the gross margin over that period was 0.0%.

EW - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Edwards Lifesciences Corporation reported a gross profit of 1.29B and revenue of 1.65B. Therefore, the gross margin over that period was 78.2%.

GMED - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Globus Medical, Inc. reported an operating income of 150.39M and revenue of 759.85M, resulting in an operating margin of 19.8%.

EW - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Edwards Lifesciences Corporation reported an operating income of 514.70M and revenue of 1.65B, resulting in an operating margin of 31.2%.

GMED - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Globus Medical, Inc. reported a net income of 124.30M and revenue of 759.85M, resulting in a net margin of 16.4%.

EW - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Edwards Lifesciences Corporation reported a net income of 380.70M and revenue of 1.65B, resulting in a net margin of 23.1%.


Frequently Asked Questions


GMED and EW have a correlation of 0.40, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

GMED has higher volatility (10.78%) compared to EW (7.56%). In terms of maximum drawdown, GMED dropped -47.91% vs EW's -54.32%.

GMED currently has the higher Sharpe Ratio (0.79 vs 0.64), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for GMED and EW

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer